US OptionsDetailed Quotes

ATRA240920C500

Watchlist

0.20
0.000.00%

15min DelayClose Jun 10 13:01 ET

0.00High0.00Low

Atara Biotherapeutics Stock Discussion

Jaguar8

Sep 6 04:19

Atara Biotherapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Adiumentum Capital Fund I LP(19.99%),Adiumentum Capital Fund I GP LLC(19.99%), etc.

$Atara Biotherapeutics (ATRA.US)$

FattyChick

Sep 5 21:15

$Atara Biotherapeutics (ATRA.US)$ Should have a re-entry at 7.70

rmgm

Sep 4 21:19

$Atara Biotherapeutics (ATRA.US)$ over 30 million cash in the books acccording to there 30th of June Financial report , will have additional extra cash of 36 million on 5 September from institutional investors and big pharma company by issuing them around 4 million shares at 8.25 $ , will further receive 20 million + 60 Million by Pierre Fabre Pharmaceuticals once FDA approves there EBV drug in Jan 2025 .
Should see increased acitivity soon as all these large investors have interest in this comp...

browny_440

Sep 4 05:47

$Atara Biotherapeutics (ATRA.US)$
good buy

Rivera

Sep 4 04:30

Trying to move up

$Atara Biotherapeutics (ATRA.US)$

Trytosaveabit

Sep 4 04:21

$Atara Biotherapeutics (ATRA.US)$ Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Jaguar8

Sep 4 04:16

NEWS

$Atara Biotherapeutics (ATRA.US)$
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
Atara Biotherapeutics (Nasdaq: ATRA) has announced a $36 million registered direct offering of common stock and pre-funded warrants. The offering, priced at $8.25 per share, represents a 15% premium to Atara's 7-day volume-weighted average price. Participants include existing top institutional investors and a new strategic investor from a large public biotechnology company. The proceeds wi...

BestFriend

Aug 31 12:46

This week ranking! keep it up.

Jaguar8

Aug 13 05:06

NEWS

$Atara Biotherapeutics (ATRA.US)$
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3...

Trytosaveabit

Jul 17 21:09

Update! Make a note!

$Atara Biotherapeutics (ATRA.US)$ Reuters· PDUFA for BLA is January 20th
Atara Biotherapeutics- Bla Acceptance Triggers $20 Mln Milestone Payment With Additional $60 Mln Milestone if Approved by FDA

No comment yet